Literature DB >> 9635527

Mesenchymal chondrosarcoma of the jaw bones: clinicopathologic study of 19 cases.

E F Vencio1, C M Reeve, K K Unni, A G Nascimento.   

Abstract

BACKGROUND: Patients with mesenchymal chondrosarcomas in general have a 5-year survival rate ranging from 42-54.6% and a 10-year survival rate of 28%. Nineteen cases of mesenchymal chondrosarcoma of the jaw bones were reviewed to study their clinicopathologic features and to compare their clinical behavior with that of mesenchymal chondrosarcomas of other locations.
METHODS: The patients were 10 males and 9 females (age range, 2-51 years). Sixteen patients were age < 30 years, and the average age at presentation was 19 years. Eleven tumors involved the mandible and eight involved the maxilla.
RESULTS: Histologically, the classic picture of a bimorphic tumor, composed of islands of well differentiated hyaline cartilage juxtaposed to a small cell undifferentiated malignancy, was present in every case. Resection, including hemimandibulectomy and hemimaxillectomy, was the main treatment in 16 patients. Seven patients had local recurrence, and five patients developed distant metastases. Six patients died of disease, and the 5-year and 10-year survival rates were 82% and 56%, respectively.
CONCLUSIONS: Mesenchymal chondrosarcoma of the jaw bones appears to have a more indolent course than mesenchymal chondrosarcoma of other anatomic

Entities:  

Mesh:

Year:  1998        PMID: 9635527     DOI: 10.1002/(sici)1097-0142(19980615)82:12<2350::aid-cncr8>3.0.co;2-w

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  15 in total

1.  Update on cartilage forming tumors of the head and neck.

Authors:  Carrie Y Inwards
Journal:  Head Neck Pathol       Date:  2007-11-27

2.  The spectrum of gnathic osteosarcoma: caveats for the clinician and the pathologist.

Authors:  Ricardo J Padilla; Valerie A Murrah
Journal:  Head Neck Pathol       Date:  2010-11-03

Review 3.  Distant metastasis from oral cavity-correlation between histopathology results and primary site.

Authors:  Yuka Uchiyama; Tadashi Sasai; Atsutoshi Nakatani; Hiroaki Shimamoto; Tomomi Tsujimoto; Sven Kreiborg; Shumei Murakami
Journal:  Oral Radiol       Date:  2020-05-28       Impact factor: 1.852

4.  Survival in Mesenchymal Chondrosarcoma Varies Based on Age and Tumor Location: A Survival Analysis of the SEER Database.

Authors:  Brian A Schneiderman; Stephanie A Kliethermes; Lukas M Nystrom
Journal:  Clin Orthop Relat Res       Date:  2017-03       Impact factor: 4.176

5.  Radiation therapy is associated with fewer recurrences in mesenchymal chondrosarcoma.

Authors:  Satoshi Kawaguchi; Israel Weiss; Patrick P Lin; Winston W Huh; Valerae O Lewis
Journal:  Clin Orthop Relat Res       Date:  2014-03       Impact factor: 4.176

6.  Huge mesenchymal chondrosarcoma of mandible.

Authors:  Hari Ram; Shadab Mohammad; Nuzhat Husain; Gaurav Singh
Journal:  J Maxillofac Oral Surg       Date:  2011-03-25

7.  [First description of mesenchymal chondrosarcoma of the lateral skull base in a 9-year-old boy].

Authors:  A Glien; O Moser; F Göke; K Wilhelm; A O H Gerstner
Journal:  HNO       Date:  2012-12       Impact factor: 1.284

Review 8.  Mesenchymal chondrosarcoma of bone and soft tissue: a systematic review of 107 patients in the past 20 years.

Authors:  Jie Xu; Dasen Li; Lu Xie; Shun Tang; Wei Guo
Journal:  PLoS One       Date:  2015-04-07       Impact factor: 3.240

9.  Mesenchymal Chondrosarcoma in Children and Young Adults: A Single Institution Retrospective Review.

Authors:  Michael W Bishop; Jessica M Somerville; Armita Bahrami; Sue C Kaste; Rodrigo B Interiano; Jianrong Wu; Shenghua Mao; Frederick A Boop; Regan F Williams; Alberto S Pappo; Sandeep Samant
Journal:  Sarcoma       Date:  2015-06-03

10.  Mesenchymal chondrosarcoma of the right buccal region: A case report and review of the literature.

Authors:  Lijiang Yu; Mingliang Li; Runtai Lin; Yue Mu; Jizhi Zhao
Journal:  Oncol Lett       Date:  2014-10-09       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.